Bowman Heiden

Dr. Heiden is currently the Director of the Center for Intellectual Property (CIP), which is a joint center for knowledge-based business development between University of Gothenburg, Chalmers University of Technology, and the Norwegian University for Science and Technology. He is also the Executive Director of the Tusher Center for the Management of Intellectual Capital at UC-Berkeley and co-chair of the Technology, Innovation, and Intellectual Property program at the Classical Liberal Institute at the NYU School of Law. Dr. Heiden was recently a member of the European Commission High-Level Expert Group on Standard Essential Patents.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More